LINEAGE CELL THERAPEUTICS IN's ticker is LCTX and the CUSIP is 53566P109. A total of 127 filers reported holding LINEAGE CELL THERAPEUTICS IN in Q4 2021. The put-call ratio across all filers is 0.20 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $28,047 | -16.3% | 23,769 | 0.0% | 0.00% | – |
Q2 2023 | $33,514 | +5.5% | 23,769 | +12.3% | 0.00% | – |
Q1 2023 | $31,760 | +34.6% | 21,173 | +5.0% | 0.00% | – |
Q4 2022 | $23,602 | -1.7% | 20,173 | -4.5% | 0.00% | – |
Q3 2022 | $24,000 | -22.6% | 21,115 | +7.7% | 0.00% | – |
Q2 2022 | $31,000 | +3.3% | 19,613 | 0.0% | 0.00% | – |
Q1 2022 | $30,000 | -26.8% | 19,613 | +16.7% | 0.00% | – |
Q4 2021 | $41,000 | -2.4% | 16,813 | 0.0% | 0.00% | – |
Q3 2021 | $42,000 | -12.5% | 16,813 | 0.0% | 0.00% | – |
Q2 2021 | $48,000 | +20.0% | 16,813 | -0.3% | 0.00% | – |
Q1 2021 | $40,000 | +14.3% | 16,857 | -15.2% | 0.00% | – |
Q4 2020 | $35,000 | +218.2% | 19,878 | +76.3% | 0.00% | – |
Q3 2020 | $11,000 | +10.0% | 11,278 | 0.0% | 0.00% | – |
Q2 2020 | $10,000 | +11.1% | 11,278 | 0.0% | 0.00% | – |
Q1 2020 | $9,000 | -18.2% | 11,278 | -8.1% | 0.00% | – |
Q4 2019 | $11,000 | -8.3% | 12,278 | +0.5% | 0.00% | – |
Q3 2019 | $12,000 | – | 12,213 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Defender Capital, LLC. | 5,036,720 | $14,354,000 | 4.77% |
BROADWOOD CAPITAL INC | 34,005,379 | $96,915,000 | 4.33% |
Prescott General Partners LLC | 1,851,851 | $5,278,000 | 0.17% |
Raffles Associates | 43,590 | $124,000 | 0.10% |
Laidlaw Wealth Management LLC | 123,730 | $353,000 | 0.09% |
DCF Advisers, LLC | 74,500 | $212,000 | 0.08% |
Beirne Wealth Consulting Services, LLC | 45,000 | $128,000 | 0.07% |
Strategic Wealth Investment Group, LLC | 64,232 | $183,000 | 0.06% |
Paradigm, Strategies in Wealth Management, LLC | 19,775 | $56,000 | 0.05% |
Fort Sheridan Advisors LLC | 47,931 | $137,000 | 0.05% |